Last C$16.35 CAD
Change Today +0.17 / 1.05%
Volume 2.5K
NDQ On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ GM
Frankfurt
As of 3:59 PM 11/24/14 All times are local (Market data is delayed by at least 15 minutes).

novadaq technologies inc (NDQ) Snapshot

Open
C$16.18
Previous Close
C$16.18
Day High
C$16.38
Day Low
C$16.18
52 Week High
04/3/14 - C$27.39
52 Week Low
10/17/14 - C$11.68
Market Cap
907.1M
Average Volume 10 Days
3.9K
EPS TTM
C$-0.60
Shares Outstanding
55.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVADAQ TECHNOLOGIES INC (NDQ)

Related News

No related news articles were found.

novadaq technologies inc (NDQ) Related Businessweek News

No Related Businessweek News Found

novadaq technologies inc (NDQ) Details

Novadaq Technologies Inc. develops, manufactures, and commercializes fluorescence imaging products and therapeutic devices for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed. The company’s proprietary imaging platform is used to visualize blood vessels, nerves, and the lymphatic system during surgical procedures. Its SPY and SPY Elite systems are used in coronary artery bypass graft surgery, cardiovascular surgery, plastic surgery, reconstructive surgery, microsurgery, organ transplant, and gastrointestinal surgery. The company’s LUNA fluorescence angiography system enables physicians treating chronic wounds for the treatment of diabetic foot ulcers, pressure sores, and other serious chronic non-healing wounds. Its FIREFLY imaging system is used for robotic surgery; and PINPOINT endoscopic fluorescence imaging system is used for traditional endoscope and to obtain fluorescence images on demand or in a simultaneous imaging mode during minimally invasive surgery. The company also offers SPY analysis toolkit, a post-processing software that allows surgeons to enhance and apply objective analysis tools to SPY Elite and LUNA images; CO2 heart laser systems for transmyocardial revascularization; and Trapper surgical imaging system. It has operations primarily in the United States and Japan. Novadaq Technologies Inc. was founded in 2000 and is headquartered in Mississauga, Canada.

Founded in 2000

novadaq technologies inc (NDQ) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $364.1K
Co-Founder
Total Annual Compensation: $218.5K
Chief Financial Officer
Total Annual Compensation: $174.8K
Vice President of Operations
Total Annual Compensation: $174.8K
Senior Vice President of Medical Education
Total Annual Compensation: $182.5K
Compensation as of Fiscal Year 2013.

novadaq technologies inc (NDQ) Key Developments

Novadaq Technologies Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Novadaq Technologies Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $12,128,469 compared to $8,895,794 a year ago. Loss from operations was $3,691,467 compared to $1,043,825 a year ago. Income before income taxes was $3,027,997 compared to loss before income taxes of $6,894,463 a year ago. Net income and comprehensive income for the period was $3,027,997 or $0.06 per diluted share compared to net loss and comprehensive loss for the period of $6,916,963 or $0.14 per basic and diluted share a year ago. The change resulted from lower warrant reevaluation adjustment in the amount of $12.6 million, primarily due to change in share price. Cash used in operating activities was $3,642,950 compared to cash provided by operating activities of $1,385,366 a year ago. Purchase of property and equipment was $921,596 compared to $1,327,969 a year ago. For the nine months, the company reported total revenues of $33,578,847 compared to $24,272,186 a year ago. Loss from operations was $12,524,544 compared to $3,971,312 a year ago. Loss before income taxes was $6,802,354 compared to $19,519,659 a year ago. Net loss and comprehensive loss for the period was $6,802,354 or $0.22 per diluted share compared to $19,587,159 or $0.43 per basic and diluted share a year ago. Cash used in operating activities was $14,982,064 compared to $2,883,446 a year ago. Purchase of property and equipment was $5,237,984 compared to $4,466,186 a year ago. Purchase of intangible assets including transaction costs was $6,368,753 against $2,477,414 a year ago.

Novadaq Technologies Inc. Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 09:30 AM

Novadaq Technologies Inc. Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 09:30 AM. Venue: The Westin Grand Central, New York, New York, United States.

Novadaq Technologies Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 01:50 PM

Novadaq Technologies Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 01:50 PM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Arun Menawat, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NDQ:CN C$16.35 CAD +0.17

NDQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CryoLife Inc $10.10 USD +0.29
View Industry Companies
 

Industry Analysis

NDQ

Industry Average

Valuation NDQ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.0x
Price/Book 4.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVADAQ TECHNOLOGIES INC, please visit www.novadaq.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.